Navigation Links
NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
Date:1/13/2010

DURHAM, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced today that the company's common stock will begin trading on the NASDAQ Capital Market with the opening of trading on Friday, January 15, 2010. The shares will continue to trade under the symbol OXBT.

In addition, company chairman and CEO Chris Stern will be in New York to ring the opening bell at the NASDAQ one week later on Friday, January 22.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte™) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

SOURCE Oxygen Biotherapeutics, Inc.

RELATED LINKS
http://www.oxybiomed.com

'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
2. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
3. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
4. Mylan Added to NASDAQ-100 Index
5. Dynatronics Receives 180-Day NASDAQ Extension
6. China Biologic Products Approved to List on NASDAQ
7. Henry Schein to Present at the NASDAQ OMX 23rd Investor Program
8. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
10. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
11. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... York , March 29, 2017 ... published a report, which provides an exhaustive study ... the study, nearly 242 companies are functional in ... and competitive. With the leading companies, such as ... Pharma LP, focusing aggressively on various marketing strategies ...
(Date:3/29/2017)... 2017  The Pharmaceutical Care Management Association (PCMA) today ... on patient out-of-pocket spending: ... (CMS), the average amount spent out-of-pocket for drugs continues ... in 2016, down from 23% in 2006. ... a coverage problem. Health plans don,t have unlimited funds ...
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... Minn. (PRWEB) , ... March 29, 2017 , ... ... medical office buildings (MOBs) and other outpatient facilities, and who are the most ... exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found that ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with wearing oral braces. "The rubber bands used in conjunction with my braces ... I decided to design a way to prevent this problem." The O.B.S. was ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), will ... education conference for clinicians who manage some of the most difficult-to-treat forms of ... The program will be led by co- chairs Dr. John Marshall, chief of ...
Breaking Medicine News(10 mins):